TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D
Rattachement africain : de, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND AIMS: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV treatment may influence immune cells in patients with CHD and performed a high-resolution analysis of natural killer (NK) cells before and during BLV therapy. APPROACH AND RESULTS: BLV-treated patients with CHD (n=20) from a single-center cohort were longitudinally analyzed for clinical, molecular, and virological parameters. Peripheral blood mononuclear cells were studied at baseline, and therapy weeks 3 and 48 by spectral flow cytometry. Healthy donors, patients with chronic hepatitis C after direct-acting antiviral treatment, and patients with chronic hepatitis B were used as controls. Overall, NK cell frequencies remained stable during BLV treatment. However, biochemical responders showed distinct NK cell immunophenotypic features before and during therapy. TIGIT expression increased on CD56 dim and CD56 bright NK cells during the course of BLV treatment and inversely correlated with ALT levels in CHD but not patients with CHC or CHB. High frequencies of TIGIT - CD57 + CD56 dim NK cells at baseline and low levels during therapy were indicative of a biochemical response. CONCLUSIONS: We here suggest that lacking the expression of the immune checkpoint inhibitor TIGIT on NK cell subtypes may be a hallmark of liver inflammation in HDV infection. BLV therapy is associated with a reappearance of TIGIT on these cells, which may be one mechanism of why liver enzymes rapidly improve during therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D
- Date Crossref
- 23/01/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Medizinische Hochschule Hannover pays non établi dans la noticeUniversité ou école supérieure
-
Centre for Individualised Infection Medicine pays non établi dans la noticeStructure de recherche
-
German Center for Infection Research pays non établi dans la noticeStructure de recherche
-
Helmholtz Centre for Infection Research pays non établi dans la noticeStructure de recherche
-
Karolinska University Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Karolinska Institutet pays non établi dans la noticeUniversité ou école supérieure
-
Department of Gastroenterology pays non établi dans la noticeInstitution
-
ZIB Program pays non établi dans la noticeInstitution
-
Cluster of Excellence RESIST pays non établi dans la noticeInstitution
-
D-SOLVE Consortium pays non établi dans la noticeInstitution
-
Institute of Virology pays non établi dans la noticeStructure de recherche
Medizinische Hochschule Hannover, Centre for Individualised Infection Medicine et German Center for Infection Research, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.